By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ono Pharmaceutical Company, Ltd. 

2-1-5 Doshomachi
Osaka    541-8526  Japan
Phone: 06-6222-5551 Fax:



Company News
Merus (MRUS) Receives Milestone Payment From Ono Pharma (OPHLY) For Selection Of Bispecific Antibody Candidate For Clinical Development And Extends Partnership With CMC Service Agreement 10/19/2016 7:49:51 AM
Bristol-Myers Squibb (BMY)'s $4 Billion Disaster Sends Partner Ono Pharma (OPHLY)'s Stock Plunging 8/8/2016 6:34:42 AM
Celyad Hammers Out NKR-2 T-cell Immunotherapy Deal Worth $311.5 Million with Ono Pharma 7/11/2016 6:06:18 AM
How a $150,000 Drug Created with Bristol-Myers Squibb (BMY) Saved Ono Pharma 3/4/2016 7:06:29 AM
Ono Pharmaceutical Company, Ltd. Transforms Its High-Throughput Screening With Genedata AG Screener 2/23/2016 10:03:05 AM
Ono Pharmaceutical Company, Ltd. Selects Medidata To Power Clinical Trials Exploring Additional Cancer Indications For Immunotherapy Drug OPDIVO (Nivolumab) 1/27/2016 10:16:06 AM
Merus Reaches Pivotal Milestone In Bispecific Antibody Collaboration With Ono Pharmaceutical Company, Ltd. 4/8/2015 10:02:22 AM
Dako A/S (Acquired by Agilent Technologies, Inc.) (A) And Ono Pharmaceutical Company, Ltd. Announce Collaboration On Development Of PD-L1 Companion Diagnostic Test For Investigational Cancer Drug Opdivo(Nivolumab) 2/16/2015 8:53:21 AM
Ono Pharmaceutical Company, Ltd. And Gilead Sciences, Inc. (GILD) Announce Exclusive License Agreement To Develop BTK Inhibitor, ONO-4059, For The Treatment Of B-Cell Malignancies And Other Diseases 12/19/2014 11:44:30 AM
Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company (BMY), And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors 12/10/2014 9:19:38 AM